Background: Prescribing criteria have been suggested for proprotein convertase subtili-
| INTRODUCTION
A substantial difference exists between the world of clinical trials and routine practice. Pro-protein convertase subtilisin kexin-9 (PCSK-9) inhibitors are novel medications which reduce total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C).
1 They have been investigated in a variety of populations including familial hypercholesterolaemia (FH), 2,3 patients with established cardiovascular disease (CVD), 2, 3 and patients intolerant to statins. 4, 5 Guidelines for the prescription of PCSK-9 inhibitors have been suggested in a number of countries and by specialist societies [6] [7] [8] [9] given the substantial expense of these agents compared with other lipid-lowering drugs. 10, 11 However, phase 3 studies have closely defined inclusion and exclusion criteria, recruit selectively, and do not cover the full spectrum of patients seen in lipid clinics in routine clinical practice. This study presents the results of an audit of sequential prescriptions in two lipid clinic practices covering both a district general hospital (DGH) and a university hospital (UH) secondary/ tertiary referral service. The DGH service comprises a single-handed physician with basic laboratory support seeing approximately 600 patients serving a local catchment of 350 000 while the UH services have three physicians, a specialist nurse and access to specialist lipid and genetic laboratory services and see 2400 patients to serve a local catchment of 350 000 and regional catchment of 2 500 000 patients.
| METHODS
A prospectively specified audit was conducted of consecutive patients considered eligible for PCSK-9 inhibitors immediately following their licensing and reimbursement approval in the UK in two clinical services.
Prescription of PCSK-9 inhibitor therapy was initiated using National
Institute of Health and Clinical Excellence (NICE) criteria for patients on maximally tolerated lipid-lowering therapy: patients with FH and LDL-C > 5 mmol/L; patients with established coronary heart disease (CHD) and LDL-C > 4 mmol/L; and patients with multi-vascular disease and LDL-C > 3.5 mmol/L. 6, 7 The services comprised a DGH providing secondary care services for a population of 450 000 and a UH providing secondary and tertiary care services for a population of 1 million.
Patients were assessed by UK NICE criteria for prescription of a PCSK-9
inhibitor. Clinical characteristics of patients were recorded including diagnosis, CVD risk factors and biochemical characteristics. Laboratory analyses comprised renal function, transaminases, creatine kinase (CK), lipid profiles including cholesterol, triglycerides, high-density lipoproteincholesterol (HDL-C) and calculated LDL-C. Apolipoprotein (apo) A-1, apo B 100 and lipoprotein (a) were measured in the university centre. All analyses were conducted using standard automated methods in accredited laboratories using Roche (Burgess Hill, UK) analytical systems. Patients were re-assessed 6-12 weeks after the initial prescription.
Data were collected on the basis of preinitiation and last observations. For patients with rare disorders additional data was obtained after secondary interventions. The data were analysed by mean and standard deviation for all normally distributed values and median and range for non-normally distributed variables. Groups were compared using Student's t test for normally distributed data and by Wilcoxon rank statistics for non-normally distributed data.
| RESULTS
Over the period July 2016-December 2016 105 patients were prescribed PCSK-9 inhibitors. The clinical characteristics of patients assessed in this study and results of treatment are shown in FH, a patient with heterozygous FH because of a PCSK-9 mutation with mild myalgia; primary muscle diseases e.g. mitochondrial myopathy (n = 1), muscular dystrophy carriers (n = 2); myasthenia gravis (n = 1); malignant hyperthermia (ryanodine receptor mutation) carrier (n = 1), nephrotic syndrome or renal transplant (n = 2), Human immunodeficiency virus (HIV) disease (n = 1); severe hypertriglyceridaemia and statin intolerance (n = 2); lecithyl-cholesterol acyl transferase (LCAT) and CVD (n = 1). Three patients had previous documented rhabdomyolysis (CK >10 000 IU/L) on statin while others participated in extreme endurance sports (n = 2). Some statin therapy was taken by 51%, 54% were on ezetimibe; 6% on fibrate, 1% bile acid sequestrants and 4% were receiving treatment with omega-3 fatty acids.
The populations treated had similar lipid levels in both cen- and 6% receiving 140 mg monthly) and alirocumab in 23% (75% alirocumab 75 mg and 25% receiving 150 mg). PCSK-9 therapy was tried and then discontinued by time of review in 15% of patients. In the DGH 25% discontinued compared with 7% in the UH (P = .02).
In patients adherent with therapy PCSK-9 inhibitor treatment re- 
What's new
• Pro-protein subtilisin kexin-9 inhibitor therapy was efficacious and well-tolerated even in patients with primary or secondary muscle diseases.
was initially ineffective in seven patients (<10% reduction or increase in LDL-C) but only formally discontinued in four patients:
• a patient with type 5 lipoproteinaemia intolerant to statins (discontinued);
• a patient with CVD and remnant hyperlipidaemia poorly tolerant to statins who later responded to PCSK-9 therapy after introduction of fenofibrate 160 mg;
• a patient with poorly controlled type 2 diabetes (discontinued);
• a patient with mixed hyperlipidaemia and nephrotic syndrome who later responded after addition of a thiazolidinedione (pioglitazone);
• a patient with a PCSK-9 D129N mutation previously well controlled on statin and ezetimibe but with myalgia proved unresponsive to PCSK9 inhibitor monotherapy but did achieve adequate response after re-introduction of ezetimibe (LDL-C 1.8 mmol/L);
• a patient with LCAT deficiency (discontinued);
• a patient with idiopathic thrombocytopenic purpura (ITP) with reduction in platelets with statin therapy showed a low response (LDL-C reduction <25%) but no adverse effect on platelet count with evolocumab therapy (discontinued).
A subgroup analysis was conducted in patients with FH. This group comprised 78 patients including one 'homozygote' (double heterozygote for LDLR V806 fs and PCSK9 R496W mutations). One patient had a PCSK9 D129N mutation. Statin intolerance was seen in 68%; CHD in 38% and poly-vascular disease in 25%. The average age was 61 ± 11 years and initial LDL-C was 5.58 ± 1.82 mmol/L. PCSK-9 therapy reduced LDL-C by 43 ± 20% (2.29 ± 1.09 mmol/L; P < .001); apoB by 32 ± 21% (P < .001) and Lp(a) by 26% (P = .03). PCSK-9 therapy was discontinued by 15% of patients mostly because of myalgia.
An analysis of 70 patients intolerant to statins was performed. The average age was 64 ± 10 years with LDL-C 5.3 ± 2.2 mmol/L, CHD was present in 38% and poly-vascular disease in 28%. PCSK-9 therapy reduced LDL-C by 43 ± 19% (2.10 ± 1.48 mmol/L; P < .001); apoB by 36 ± 20% (P < .001) and Lp(a) by 28 ± 33% (P = .18). PCSK-9 therapy was discontinued by 22% of patients.
| DISCUSSION
The treatment of LDL-C has proved an increasing challenge over the last few years as the evidence and guidelines have suggested that all patients with established CVD need to receive high dose high intensity statin therapy while those at increased risk of CVD in primary prevention should receive moderate dose statin therapy. 12-14 About 25% of the workload of lipid clinics is the management of patients Data presented as mean and standard deviation except where indicated *P < .05; ***P < .001.
with statin intolerance usually caused by myalgia. 15 This occurs in up to 20% of patients in simply reported studies and 1%-2% of patients in strictly observed prospective studies with evidence of re-challenge. 16 Statin therapy is contra-indicated in patients with underlying primary A number of specialist societies and reimbursement agencies (e.g.
UK NICE) have established criteria for prescription of PCSK-9 inhibi-
tors given the high costs of these agents. [6] [7] [8] [9] These guidelines tend to agree that prescription of a PCSK-9 inhibitor is reasonable in patients with established CVD or FH and LDL-C > 4 mmol/L. This UK audit was conducted in two centres comprising a DGH and a UH clinic according to NICE criteria. Both clinics use the same protocol for management of statin intolerance including intermittent statin and ezetimibe therapy. 18 The UH uses molecular diagnosis for FH and the DGH does not but this did not result in a significant difference in pretreatment LDL-C in FH patients. Both centres recruited patients with similar LDL-C but patients in the DGH had a higher prevalence of FH, greater severity of atheromatous disease and a higher prevalence of statin intolerance with 2.7 NICE criteria for PCSK-9 prescription as opposed to 1.7 in the F I G U R E 1 Efficacy of low-density lipoprotein-cholesterol (LDL-C) reduction in adherent patients receiving PCSK-9 inhibitor therapy T A B L E 2 Efficacy and safety of PCSK-9 inhibition in patients with relevant comorbidities, statin myopathy, and/or contra-indications to statins UH. In the UH clinic 36% did not obtain repeat quarterly prescriptions while all DGH patients received an initial dose but 23% discontinued statin therapy by time for review at 3 months. In patients adherent to treatment LDL-C was reduced by 41% (2.2 mmol/L) mostly using the higher doses of PCSK-9 inhibitor (74% at maximum licensed dose).
Condition Age Gender

Pre-PCSK-9 LDL-C (mmol/L)
Post-PCSK9
PCSK-9 therapy was effective producing a 70% LDL-C reduction in a 'homozygote' patient actually a double heterozygote for LDLR and PCSK-9 mutations. 19, 20 A <25% LDL-C reduction was observed in 13% of patients. Reductions in 33% in apoB (P < .001) and 28% (P = .01) in Lp(a) were observed similar to published studies.
2,21
Rates of discontinuation were 15% rising to 20% in statin intolerant patients which are similar to those reported in phase 3 placebocontrolled trials of PCSK-9 inhibitors in statin-intolerant patients. 4, 5 Adverse events -mostly myalgia were reported by 9% of patients and 4% had to have PCSK-9 therapy discontinued as it was ineffective (no change or rise in TC or LDL-C). PCSK-9 therapy was effective and well-tolerated by patients with histories of previous rhabdomyolysis, HIV dyslipidaemia, bile salt malabsorption and renal disease. All the patients with definitive diagnoses of primary or secondary muscle disease who were previously unable to tolerate statin therapy (>3 drugs including intermittent dosing) were able to tolerate PCSK-9 therapy and showed marked improvements in their lipid profiles (Table 2) .
Outcomes in other patient groups were more complex. One patient with statin intolerance, severe mixed hyperlipidaemia and nephrotic syndrome initially showed no response but later responded to PCSK-9 therapy after initiation of thiazolidinedione therapy for steroid-resistant nephrotic syndrome. In the UK, PCSK-9 therapy is only supplied by hospital pharmacies.
Patients cannot obtain repeat prescriptions through local pharmacies as the agents are subject to local NHS high-cost drugs policies which include hospital repeat scripts. Some commissioning groups (payers) require a >25% LDL-C response to continue treatment. Only 13% of patients showed a <25% LDL-C reduction in this study. One reason behind poor adherence in this audit may relate to difficulties in obtaining repeat prescriptions. Given distances that need to be travelled many patients are eligible for courier delivery of drugs through a HomeCare delivery service after initiation but the benefits of this
were not assessed in this study as arrangements were not yet in place.
While PCSK-9 therapy is well-tolerated in many patients the high rates of prescription non-renewal in a fully funded medical system (24%) or stated adverse events on initial review (15%) suggest that optimal prescribing practice would be to initiate PCSK-9 therapy, review the patient after a set period and only continue to repeat prescriptions or provide HomeCare delivery in adherent individuals.
| CONCLUSION
This audit study shows that the NICE criteria for prescription of PCSK-9 inhibitors are easy to follow, and are practical in identifying high-risk patients who often qualify by meeting multiple criteria. A substantial fraction of patients (25%) did not collect or did not renew their prescriptions after the initial dose with myalgia being the principal adverse event recorded if the drug had been taken initially.
However, patients with documented muscle disease showed a good response to PCSK-9 therapy with no adverse events. In patients adherent with PCSK-9 therapy LDL-C was reduced by 41% (2.1 mmol/L).
This study suggests that NICE criteria are appropriate for the prescription for PCSK-9 inhibitor therapy but that prescriptions should not be changed to long-term delivery services until patients have been reviewed and shown to be adherent. 
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